Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Collaborative Neuroscience Network, LLC

Neither a doctor nor a teaching hospital

Research payments

$5,968,752

187 payments

Through program year 2025, Collaborative Neuroscience Network, LLC is reported as receiving $5,968,752 in research payments, across 187 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $134,590 5
2024 Research $533,577 6
2023 Research $4,548,570 72
2022 Research $632,013 33
2021 Research $42,030 24
2020 Research $36,498 18
2019 Research $41,474 29

Breakdown

Who paid Research payments · program years 2019–2025
  1. Ipsen Bioscience Inc $4,927,582 76 payments
  2. Sage Therapeutics, Inc. $639,199 7 payments
  3. E.R. Squibb & Sons, L.L.C. $133,784 5 payments
  4. AstraZeneca UK Limited $92,088 3 payments
  5. Avanir Pharmaceuticals, Inc. $84,506 31 payments
  6. AstraZeneca Pharmaceuticals LP $39,871 2 payments
  7. Grifols Biologicals LLC $21,318 2 payments
  8. Merck Sharp & Dohme Corporation $13,000 1 payment
  9. Acorda Therapeutics, Inc $7,500 1 payment
  10. Celgene Corporation $4,904 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase I, Single-Centre, Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants $2,647,670 25 payments
  2. PK Japan $2,279,911 51 payments
  3. A 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Study to Evaluate the Effect of Sage-718 on Functioning Capacity in Participants With Huntington's Disease $318,313 3 payments
  4. A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment $208,566 2 payments
  5. A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder $112,210 1 payment
  6. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Sage-718 in Participants With Mild Cognitive Impairment Or Mild Dementia Due to Alzheimer's Disease $102,547 1 payment
  7. 18-Avp-786-207 $81,506 28 payments
  8. A Phase 1, Multi-center, Open-label, 3-arm, Fixed Sequence Study to Assess the Effect of Co-administration of AZD9833 on the Pharmacokinetics of Midazolam (CYP3A4/5 Substrate), of Omeprazole (CYP2C19 Substrate), of Celecoxib (CYP2C9 Substrate) and of Dabigatran etexilate (P-gp Transporter Substrate) in Healthy Postmenopausal Female Volunteers $57,969 2 payments
  9. Phase 1, Randomized, Open label, Three-arm, Single Dose, Parallel Group Study to Compare AZD7442 (AZD8895 and AZD1061) Pharmacokinetic Exposure Following Intramuscular Administration as a Co-formulation versus Administration from Two Separate Vials of the Individual Monoclonal Antibodies in Adult Healthy Participants $39,871 2 payments
  10. A Randomized Double-blind Placebo-controlled Study of the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of MEDI1341 in Subjects with Parkinsons Disease $34,119 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record